Newly published phase 2b trial data show those treated with roflumilast cream had significantly greater…
Publication details the efficacy and safety of rezafungin dosed once-weekly versus the current of care…
BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage…
WATERTOWN, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology…
IND filing followed encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed…
Novel best-in-class MEK-RAF complex inhibitor IK-595 targets RAS pathway; IND in 2023 Novel paralog-selective TEAD…
SAN DIEGO, Nov. 28, 2022 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today provided…
CNM-Au8 demonstrated low contrast vision improvement and global neurological improvement (low contrast vision, cognition, upper…
Innovative trial addresses second most common dementia after Alzheimer’s disease, now enrolling patients at up…
ROCHESTER, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology…
THE WOODLANDS, Texas, Nov. 28, 2022 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today…
MALVERN, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ:…
Study finds patients with Fragile X who have a highly methylated FMR1 gene that were…
Primary endpoint in Intention to Treat (ITT) was not met despite large absolute reductions in…
– PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects – –…
RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today…
PRESS RELEASE Emergex Generates Chikungunya Ligandome, a Milestone in the Development of its T cell…
PRESS RELEASE Oxitope Appoints Leading Interventional Cardiologist Gregg Stone to Advisory Board for Myocardial Reperfusion…
WALTHAM, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company…
Replay receives $1.5 million grant for its hypoimmunogenic technology platform Replay developing uCell™, its universal,…